{"References": [{"title": "FGFR2 fusions as a target for precision medicine in cholangiocarcinoma", "authors": "Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A", "journal": "Cancer Discovery", "year": "2017", "volumes": "7", "first page": "252", "last page": "263", "DOI": "10.1158/2159-8290.CD-16-1000"}, {"title": "Mechanisms of acquired resistance to FGFR kinase inhibitors in FGFR2 fusion-positive cholangiocarcinoma", "authors": "Goyal L, Shi L, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A", "journal": "Cancer Research", "year": "2017", "volumes": "77", "first page": "3286", "last page": "3297", "DOI": "10.1158/0008-5472.CAN-16-3176"}, {"title": "FGFR2 gene fusions in intrahepatic cholangiocarcinoma", "authors": "Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T", "journal": "Clinical Cancer Research", "year": "2014", "volumes": "20", "first page": "3084", "last page": "3091", "DOI": "10.1158/1078-0432.CCR-13-2171"}, {"title": "Targeting FGFR in cholangiocarcinoma: The new frontiers", "authors": "Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Wolff RA, Ewald F, Efrat N", "journal": "Hepatology", "year": "2019", "volumes": "69", "first page": "2313", "last page": "2325", "DOI": "10.1002/hep.30321"}, {"title": "FGFR2 alterations in cholangiocarcinoma: Implications for therapy", "authors": "Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T", "journal": "Oncotarget", "year": "2014", "volumes": "5", "first page": "8089", "last page": "8097", "DOI": "10.18632/oncotarget.2401"}, {"title": "The role of FGFR2 in cholangiocarcinoma: From molecular pathogenesis to targeted therapies", "authors": "Goyal L, Muzumdar MD, Zhu AX", "journal": "Journal of Hepatology", "year": "2015", "volumes": "62", "first page": "1447", "last page": "1453", "DOI": "10.1016/j.jhep.2015.02.029"}, {"title": "FGFR2 fusions and other alterations in cholangiocarcinoma: Clinical and molecular insights", "authors": "Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A", "journal": "Cancer Research", "year": "2017", "volumes": "77", "first page": "3286", "last page": "3297", "DOI": "10.1158/0008-5472.CAN-16-3176"}, {"title": "FGFR2 fusions in cholangiocarcinoma: A new therapeutic target", "authors": "Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T", "journal": "Oncotarget", "year": "2014", "volumes": "5", "first page": "8089", "last page": "8097", "DOI": "10.18632/oncotarget.2401"}, {"title": "FGFR2 fusions in cholangiocarcinoma: A new therapeutic target", "authors": "Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T", "journal": "Oncotarget", "year": "2014", "volumes": "5", "first page": "8089", "last page": "8097", "DOI": "10.18632/oncotarget.2401"}, {"title": "FGFR2 fusions in cholangiocarcinoma: A new therapeutic target", "authors": "Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T", "journal": "Oncotarget", "year": "2014", "volumes": "5", "first page": "8089", "last page": "8097", "DOI": "10.18632/oncotarget.2401"}]}